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Abstract
Background: Surfactant proteins are produced predominantly by alveolar type II (ATII) cells, and the expression of
these proteins can be altered by cytokines and growth factors. Th1/Th2 cytokine imbalance is suggested to be
important in the pathogenesis of several adult lung diseases. Recently, we developed a culture system for
maintaining differentiated adult human ATII cells. Therefore, we sought to determine the effects of IL-13 and IFN-g
on the expression of surfactant proteins in adult human ATII cells in vitro. Additional studies were done with rat
ATII cells.
Methods: Adult human ATII cells were isolated from deidentified organ donors whose lungs were not suitable for
transplantation and donated for medical research. The cells were cultured on a mixture of Matrigel and rat-tail
collagen for 8 d with differentiation factors and human recombinant IL-13 or IFN-g.
Results: IL-13 reduced the mRNA and protein levels of surfactant protein (SP)-C, whereas IFN-g increased the
mRNA level of SP-C and proSP-C protein but not mature SP-C. Neither cytokine changed the mRNA level of SP-B
but IFN-g slightly decreased mature SP-B. IFN-g reduced the level of the active form of cathepsin H. IL-13 also
reduced the mRNA and protein levels of SP-D, whereas IFN-g increased both mRNA and protein levels of SP-D.
IL-13 did not alter SP-A, but IFN-g slightly increased the mRNA levels of SP-A.
Conclusions: We demonstrated that IL-13 and IFN-g altered the expression of surfactant proteins in human adult
ATII cells in vitro. IL-13 decreased SP-C and SP-D in human ATII cells, whereas IFN-g had the opposite effect. The
protein levels of mature SP-B were decreased by IFN-g treatment, likely due to the reduction in active form
cathpesin H. Similarly, the active form of cathepsin H was relatively insufficient to fully process proSP-C as IFN-g
increased the mRNA levels for SP-C and proSP-C protein, but there was no increase in mature SP-C. These
observations suggest that in disease states with an overexpression of IL-13, there would be some deficiency in
mature SP-C and SP-D. In disease states with an excess of IFN-g or therapy with IFN-g, these data suggest that
there might be incomplete processing of SP-B and SP-C.
Background
The alveolar type II (ATII) cell produces pulmonary sur-
factant and most of the surfactant proteins in the lung.
The four surfactant proteins, SP-A, SP-B, SP-C and SP-
D, have been shown to play pivotal roles in the regula-
tion of surfactant lipid metabolism, lipid membrane
organization and host defense in the lung [1]. Dysregu-
lation of surfactant protein expression has been
postulated to be important in the pathogenesis of sev-
eral lung diseases [2-7]. Alterations in these proteins
likely have important consequences for overall lung
homeostasis and defense against pathogens.
SP-A and SP-D are water-soluble and belong to the
collectin subgroup of C-type lectins [8]. SP-A genetic
variants are predisposed to both interstitial pulmonary
fibrosis (IPF) and lung cancer [2,3]. SP-A-/- mice show
increased susceptibility to bacterial, viral and fungal
pathogens but have no reported lung structural abnorm-
alities [9]. SP-D-/- mice spontaneously develop emphy-
sema and fibrosis, which is thought to be the result of
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dant metabolism and matrix metalloproteinase (MMP)
activity [10]. Both SP-A and SP-D knockout mice have
increased lung inflammation when they are infected
with bacteria or viruses compared to wild-type strains
[11]. SP-A and/or SP-D concentration in bronchoalveo-
lar lavage fluid (BALF) are significantly decreased in
patients with acute respiratory distress syndrome
( A R D S ) ,I P F ,c o l l a g e nv a s c u l a r disease associated inter-
stitial pneumonia, hypersensitivity pneumonia, sarcoido-
sis and cystic fibrosis [12-15]. Van De Graaf et al. found
that SP-A is decreased in BALF from patients with
bronchial asthma [16], whereas Cheng, G. et al. reported
increased amounts of SP-A in both bronchial and alveo-
lar lavage and increased levels of SP-D in alveolar lavage
fluid but not bronchial lavage fluid in patients with
asthma [17]. Cigarette smoking is reported to reduce
SP-A and SP-D levels in BALF [18,19]. Although SP-A
and SP-D are thought to be important components in
innate immunity, there has not been an association of
genetic deficiencies of SP-A or SP-D in humans with
recurrent or persistent respiratory infections.
SP-B and SP-C are extremely hydrophobic and play
critical roles in the biophysical functions of surfactant
[20]. Polymorphisms of the SP-B gene are reported to
be associated with squamous cell carcinoma of lung [4],
risk for acute respiratory distress syndrome (ARDS) [5]
and chronic obstructive pulmonary disease (COPD) [6].
Recent studies have revealed that some familial forms of
pulmonary fibrosis are associated with mutations in the
SP-C gene [7]. Depending on the genetic background,
SP-C deficient mice can spontaneously develop chronic
inflammation and have increased and prolonged pul-
monary fibrosis following intratracheal instillation of
bleomycin [21].
IL-13 is a pleiotropic cytokine and a major effector
molecule at sites of Th2 inflammation and tissue remo-
deling. IL-13 is a potent stimulator of eosinophilic, lym-
phocytic, and macrophage-dominant inflammation,
mucus metaplasia, and fibrosis. [22-27]. IL-13 dysregula-
tion plays an important role in the pathogenesis of a
variety of lung diseases including asthma, IPF, viral
pneumonia, and COPD [22,28-33]. In addition, BALF
f r o mI L - 1 3o v e r e x p r e s s i n gm i c eh a v ea3 -t o6 - f o l d
increase in surfactant phospholipids, a 2- to 3-fold
increase in SP-A, -B, and -C, and a 70-fold increase in
SP-D [34]. In neonatal rat ATII cells, IL-4 and IL-13,
but not IFN-g, increases intracellular SP-D, but levels of
other surfactant proteins were not reported [35].
IFN-g is the prototypic Th1 cytokine and is known to
play a key role in the regulation of diverse immune
responses [36]. Dysregulated IFN-g production has been
implicated in a large number of diseases, which are
related to inflammation and remodeling characterized
by tissue atrophy and/or destruction [37]. In pulmonary
emphysema, alveolar septal destruction is accompanied
by increased numbers of CD8+ cells that produce IFN-g
and IFN-g inducible protein 10/CXCL10 [38,39].
Overexpression of IFN-g in mice causes pulmonary
emphysema, which is suggested to be due to cathepsin
S-dependent epithelial cell apoptosis [37,40]. In human
fetal alveolar epithelial cells in vitro, IFN-g is reported to
increase SP-A protein levels by 3-fold and SP-A mRNA
levels by 2.7-fold but does not alter SP-B and SP-C
mRNA levels [41].
Although dysregulation of the Th1/Th2 cytokine is
related to the pathogenesis of several adult lung diseases
and alterations of surfactant proteins have been reported
in variety of lung diseases, the effect of IL-13 or IFN-g
on the expression of surfactant proteins in primary
adult human ATII cells has not been reported. Methods
for isolating and culturing adult rat and mouse ATII
cells and fetal human ATII cells have been available for
years, but there has been less success in maintaining the
differentiated functions of adult human alveolar epithe-
lial cells in primary culture. A variety of methods for
isolating human type II cells have been published and
some of their properties have been described [42-47],
but maintenance of surfactant protein expression in
adult human ATII cells in monolayer culture has been
difficult. Recently, we developed a system for maintain-
ing the differentiated functions of adult human ATII
cells in vitro [48]. Therefore, the aim of this study is to
investigate the IL-13 and IFN-g effect on the expression
of the surfactant proteins using primary human adult
ATII cells in monolayer culture in vitro.T h ee x p e r i -




We obtained human lungs from deidentified organ
donors whose lungs were not suitable for transplantation
and donated for medical research through the National
Disease Research Interchange (Philadelphia, PA) and the
International Institute for the Advancement of Medicine
(Edison, NJ). The Committee for the Protection of
Human Subjects at National Jewish Health approved this
research. We selected donors with reasonable lung func-
tion with a PaO2/FIO2 ratio of >250, no history of clini-
cal lung disease and a chest radiograph that did not
indicate infection, and a limited time on the ventilator.
The gender, age, and smoking history were variable and
not selection criteria. The human donors used in this
study included 6 males and 6 females with age ranges
from 10 to 72, and there were 7 current smokers and 5
nonsmokers. Hence, there was a significant amount of
variability among the donors, as expected.
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We modified the human type II cell isolation method
published by Fang and coworkers [44]. Briefly, the mid-
dle lobe was perfused, lavaged, and then instilled with
elastase (12.9 U/ml; Roche Diagnostics, Indianapolis, IN)
for 50 minutes at 37°C. The lung was minced, and the
cells were isolated by filtration and partially purified by
centrifugation on a discontinuous density gradient made
of Optiprep (Accurate Chemical Scientific Corp., West-
bury, NY) with densities of 1.080 and 1.040, and by
negative selection with CD14-coated magnetic beads
(Dynal Biotech ASA, Oslo, Norway) and binding to IgG-
coated Petri dishes (Sigma, S t .L o u i s ,M O ) .T h ec e l l s
were counted and cytocentrifuged. Cell preparations
were made to assess cell purity by staining for cytokera-
tin (CAM 5.2; Dako Cytomation, Carpinteria, CA). The
cells were stored in 10% dimethyl sulfoxide (DMSO)
and 90% fetal bovine serum (FBS) in liquid nitrogen
until they were used in these studies.
Culture of human ATII cells
The isolated cells were resuspended in Dulbecco’s Mod-
ified Eagle’s Medium (DMEM) supplemented with 10%
FBS and 2 mM glutamine, 2.5 μg/ml amphotericin B,
100 μg/ml streptomycin, 100 units/ml penicillin G
(Mediatech, Inc., Manassas, VA), and 10 μg/ml gentami-
cin (Sigma-Aldrich, St. Louis, MO). 4.0 million cells
were plated on 4.2 cm
2 millicell inserts (Millipore Corp.,
Bedford, MA) that had been previously coated with a
mixture of 50% Matrigel (BD Biosciences, Bedford, MA)
and 50% rat-tail collagen in DMEM with 10% FBS [49].
For most of our studies, after 48 h the media was chan-
ged to DMEM including 5% heat inactivated human
serum (Mediatech, Inc.) and 10 ng/ml TGFa (R&D Sys-
tems, Minneapolis, MN). Two days later, 10 ng/ml kera-
tinocyte growth factor (KGF, Amgen, Thousand Oaks,
CA) was added instead of TGFa for 4 d, and the med-
ium was changed every other day. Therefore, cells in all
conditions were cultured for a total of 8 d with or with-
out human recombinant IL-13 or IFN-g (R&D Systems)
added for the last 2, 4 or 6 d. Additional studies were
done with a slightly different set of differentiation fac-
tors: KGF(K), isomethylbutyl xanthene (I) and 8Br-
cAMP (A) for 2 d followed by KIA and dexamethasone
(D) for 4 d, designated as KIAD [48].
Rat ATII cell isolation and culture
ATII cells were isolated from pathogen-free adult male
Sprague-Dawley rats (Harlan, Indianapolis, IN) by disso-
ciation with porcine pancreatic elastase (Roche Diagnos-
tics) and partial purification on discontinuous density
gradients by methods previously described [50]. This
research was approved by the Animal Care Committee
at National Jewish Health (IACUC). Type II cells were
plated on 4.2 cm
2 millicell inserts (Millipore Corp). 2.5
million freshly isolated viable type II cells were plated in
DMEM containing 5% rat serum (RS) (Pel-Freez Biologi-
cals, Rogers, AR), 2 mM glutamine, 2.5 μg/ml ampho-
tericin B, 100 μg/ml streptomycin, 100 units/ml
penicillin G (all from Mediatech, Inc.), and 10 μg/ml
gentamicin (Sigma-Aldrich). After attachment for 24 h,
the cells were rinsed twice with DMEM and then cul-
tured in DMEM containing RS, glutamine, antibiotics
described above and 10 ng/ml KGF for 6 d with or
without recombinant rat IL-13 (20 ng/ml) or rat IFN-g
(100 ng/ml) (R&D Systems) for the last 4 d.
Immunoblotting and real-time PCR (RT-PCR)
Protein and mRNA expression of corresponding genes
were measured by western blotting and real-time RT-
PCR according to protocols as described previously
[49]. Polyacrylamide gradient gels (8-16%; Invitrogen
Corporation) run in tris glycine buffer were used to
separate proteins. Proteins were run in the reduced
state except for mature SP-B, which was run unreduced.
For western blotting, protein loading was normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The primary antibodies were mouse anti-human SP-A
(PE-10), SP-D (1G11) (a gift from Yoshio Kuroki), rab-
bit anti-rat SP-A and SP-D, rabbit anti-human proSP-B,
rabbit anti-sheep mature SP-B (Chemicon International,
Temecula, CA), rabbit anti-human proSP-C, rabbit anti-
human mature SP-C (Seven Hills Bioreagents,
Cincinnati, OH), mouse anti-human ABCA3 (Seven
Hills Bioreagents), mouse anti-human Cathepsin H, and
mouse anti-rabbit GAPDH (abcam, Cambridge, MA).
The intensities of the bands were calculated using NIH
I m a g es o f t w a r e( v e r s i o n1 . 6 2 ) .F o rr e a l - t i m eR T - P C R ,
the expression levels of genes were expressed as a ratio
to the expression of the constitutive probe 36B4, acidic
ribosomal phosphoprotein P0 [51]. The specific primers
and probes used in these experiments are listed in
Table 1.
Immunofluorescence of human proSP-C
The cells were fixed in 4% paraformaldehyde, and then
the filters were embedded in paraffin as described [52].
The primary antibodies included rabbit anti-human
proSP-C (Seven Hills Bioreagents). The secondary anti-
body was donkey Alexa Fluor 488 anti-rabbit IgG (H+L)
from Invitrogen (Corporation, Carlsbad, CA).
Statistical Analysis
All data were presented as means ± standard error of
the mean. One-way ANOVA was used to compare the
difference between two or more groups. Appropriate
post hoc tests were selected for multiple comparison.
Statistical significance was set at p < 0.05.
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Expression of surfactant proteins in adult human ATII
cells cultured on Matrigel and rat tail collagen coated
inserts with IL-13
Human ATII cells were isolated and cultured in vitro for
8 d (2 d adherence, 2 d TGFa a n d4dK G F )w i t h2o r
20 ng/ml human recombinant IL-13. The protein level
of mature SP-C showed significant dose-dependent
down-regulation by human recombinant IL-13
(Figure 1A, B). Next we used 20 ng/ml human recombi-
nant IL-13 for a time-course experiment, added it to the
cultured cells for the final 2, 4 or 6 d and evaluated the
expression of surfactant protein levels on day 8 by
immunoblotting (n = 6) (Figure 2A, B). Protein levels of
SP-A and mature SP-B were not altered by IL-13,
whereas those of mature SP-C and SP-D were greatly
down-regulated by 4 or 6 d of treatment with IL-13
(relative increase of mature SP-C: without IL-13 1.0, 2 d
IL-13 0.60 ± 0.13, 4 d IL-13 0.35 ± 0.11p = 0.001, 6 d
IL-13 0.45 ± 0.19 p = 0.005; SP-D: without IL-13 1.0, 2
d IL-13 0.66 ± 0.12, 4 d IL-13 0.47 ± 0.11 p = 0.002, 6 d
IL-13 0.46 ± 0.17 p = 0.003) (Figure 2A, B).
We then assessed whether IL-13 altered the mRNA
levels of surfactant proteins (n = 6) (Figure 3A). Consis-
tent with the protein levels (Figure 2B), mRNA levels of
SP-C and SP-D were significantly down-regulated in
Table 1 Sequence of Primer and Probes Used in This Study
Gene Name Forward Primer Probe Reverse Primer
SP-A GCCATTCAGGAGGCATGTG CGGCCGCATTGCTGTCCCA GCCTCATTTTCCTCTGGATTCC
SP-B TGGGAGCCGATGACCTATG CAAGAGTGTGAGGACATCGTCCACATCC GCCTCCTTGGCCATCTTGT
SP-C CGGGCAAGAAGCTGCTTCT CCACACCGCAGGGACAAACCCT CCACACCGCAGGGACAAACCCT
SP-D ACACAGGCTGGTGGACAGTTG CCTCTCCACGCTCTGCCGCGT TGTTGCAAGGCGGCATT
36B4 CCACGCTGCTGAACATGCT AACATCTCCCCCTTCTCCTTTGGGCTT TCGAACACCTGCTGGATGAC
Definition of abbreviations: SP, surfactant protein
Figure 1 IL-13 alters mature SP-C protein level in a dose-dependent manner. Adult human ATII cells were cultured on Matrigel and rat-tail
collagen coated inserts in DMEM containing 5% heat inactivated human serum with 2 d of TGFa followed by 4 d of KGF. Panel A shows a
representative immunoblot from ATII cells cultured with 2 or 20 ng/ml IL-13 for the final 4 days. Lane 1: day 0 control (freshly isolated ATII cells),
Lane 2: empty lane, Lane 3: 2 d 10 ng/ml TGFa + 4 d 10 ng/ml KGF, Lane 4: 2 d 10 ng/ml TGFa + 4 d 10 ng/ml KGF with 4 d 2 ng/ml IL-13,
Lane 5: 2 d 10 ng/ml TGFa + 4 d 10 ng/ml KGF with 4 d 20 ng/ml IL-13. Panel B shows the reduction in mature SP-C protein levels after
treatment with IL-13 (black) by immunoblotting data normalized to GAPDH (n = 3), which are analyzed by NIH Image. The comparison is to
cultures without IL-13. Representative data are shown in Panel A lane 3 to 5. *: p < 0.05 v.s without IL-13.
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Page 4 of 13Figure 2 IL-13 and IFN-g alter surfactant protein levels. Adult human ATII cells were cultured on Matrigel and rat-tail collagen coated inserts
in DMEM containing 5% heat inactivated human serum with 2 d of TGFa followed by 4 d of KGF. Panel A shows representative immunoblot
from ATII cells cultured with 20 ng/ml IL-13 for 2, 4 or 6 d or with 100 ng/ml IFN-g for 4 d. Lane 1: day 0 control, Lane 2: empty lane, Lane 3: 2
d 10 ng/ml TGFa + 4 d 10 ng/ml KGF, Lane 4: 2 d 10 ng/ml TGFa + 4 d 10 ng/ml KGF with 2 d 20 ng/ml IL-13, Lane 5: 2 d 10 ng/ml TGFa +4
d 10 ng/ml KGF with 4 d 20 ng/ml IL-13, Lane 6: 2 days 10 ng/ml TGFa + 4 d10 ng/ml KGF with 6 d 20 ng/ml IL-13, Lane 7: 2 days 10 ng/ml
TGFa + 4 d 10 ng/ml KGF with 4 d 100 ng/ml IFN-g. Panel B shows surfactant proteins levels from IL-13 (black) time-course treatment
immunoblotting data normalized by GAPDH (n = 6), which are analyzed by NIH Image. Only SP-A, mature SP-B, mature SP-C and SP-D data are
shown. The comparison is to cultures without IL-13. Representative data are shown in Panel A lane 3 to 6. *: p < 0.05 v.s without IL-13. Panel C
shows surfactant proteins levels from IFNg treatment (gray) immunoblotting data normalized by GAPDH (n = 6), which are analyzed by NIH
Image. Representative data are shown in Panel A lane 3 and 7. *: p < 0.05 v.s without IFN-g.
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Page 5 of 13Figure 3 IL-13 and IFN-g alter surfactant protein mRNA levels. Adult human ATII cells were cultured on Matrigel and rat-tail collagen coated
inserts in DMEM containing 5% heat inactivated human serum with 2 d TGFa followed by 4 d KGF. Panel A shows mRNA data from ATII cells
cultured with 20 ng/ml IL-13 (black) for 2, 4 or 6 d. mRNA levels for surfactant proteins were measured by quantitative real-time PCR and
normalized to the constitutive probe 36B4 (n = 6). *: p < 0.05 v.s without IL-13. Panel B shows mRNA data from ATII cells cultured with 100 ng/
ml IFN-g (gray) for 4 d. mRNA levels for surfactant proteins were normalized to the constitutive probe 36B4 by quantitative real-time PCR (n = 6).
*: p < 0.05 v.s without IFN-g.
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Page 6 of 13response to 2, 4 or 6 d of IL-13 treatment (relative
increase of SP-C: without IL-13 1.0, 2 d IL-13 0.38 ±
0.05 p < 0.001, 4 d IL-13 0.29 ± 0.07 p < 0.001, 6 d
IL-13 0.42 ± 0.13 p < 0.001; SP-D: without IL-13 1.0, 2
d IL-13 0.48 ± 0.06 p < 0.001, 4 d IL-13 0.47 ± 0.08 p <
0.001, 6 d IL-13 0.57 ± 0.10 p < 0.001) (Figure 3A).
There was no change in SP-A and SP-B mRNA levels.
We analyzed the protein level of proSP-C in the cell
lysates by immunoblotting (Figure 2A) using NIH Image
and examined proSP-C by immunofluorescence of the
cultured cells (Figure 4A, B). The protein level of
proSP-C in cell lysates from immunoblotting analysis
measured by NIH Image was significantly decreased by
IL-13 (relative increase of top band: 0.64 ± 0.11 p =
0.008, 2
nd band: 0.31 ± 0.12 p < 0.001, 3
rd band: 0.21 ±
0.04 p < 0.001, bottom band: 0.22 ± 0.07 p < 0.001)
(Figure 4A). In proportion to the protein expression of
mature SP-C, the immunofluorescent level of proSP-C
in the cells treated with IL-13 was markedly lower than
cultures without IL-13 (Figure 4B top and middle
pictures).
Expression of surfactant proteins in adult human alveolar
type II cells cultured on Matrigel and rat-tail collagen
coated inserts with IFN-g
Human ATII cells were isolated and cultured in vitro for
8 d (2 d adherence, 2 d TGFa and 4 d KGF) with 100
ng/ml human recombinant IFN-g for the last 4 d
(n = 6). We used 4 d of 100 ng/ml IFN-g for this experi-
ment based on our previous experiments with the KIAD
system (Additional File 1A right panel). The protein
levels of surfactant proteins in the cell lysates were mea-
sured by immunoblotting (Figure 2A lane 3 and 7 and
Figure 2C). SP-A and mature SP-C protein levels were
not changed by IFN-g, whereas mature SP-B protein
level was down-regulated (relative increase of mature
SP-B: without IFN-g 1.0, with IFN-g 0.55 ± 0.09 p <
0.001) and SP-D protein levels were significantly up-
regulated (relative increase of SP-D: without IFN-g 1.0,
with IFN-g 1.92 ± 0.36 p = 0.028) (Figure 2A lane 3 and
7, Figure 2C). We then assessed the IFN-g effect on
mRNA levels of surfactant proteins (n = 6). The mRNA
levels of SP-A, -C and -D were increased by IFN-g (rela-
tive increase of SP-A: without IFN-g 1.0, with IFN-g
1.68 ± 0.26 p = 0.024, SP-C: 2.93 ± 0.60 p = 0.009, SP-
D: 2.87 ± 0.28 p < 0.001) in response to 4 d of IFN-g
stimulation (Figure 3B). There was no change in SP-B
mRNA level.
We also analyzed protein level of proSP-C in the cell
lysates by immunoblotting (Figure 2A) using NIH Image
and examined proSP-C by immunofluorescence of the
cultured cells (Figure 4A, B). The protein level of
proSP-C in cell lysate from immunoblotting analysed by
NIH Image was also greatly increased by IFN-g
treatment (relative increase of top band: 2.86 ± 0.52 p =
0.005, 2
nd band: 3.28 ± 1.50 p > 0.05, 3
rd band: 3.58 ±
1.1 p > 0.05, bottom band: 2.53 ± 0.59 p = 0.040) (Fig-
ure 4A). The immunofluorescent level of proSP-C in the
cells cultured with IFN-g was remarkably higher than in
cells without IFN-g (Figure 4B top and bottom pictures),
and IFN-g treated cells possessed highly stained small
dots in the cells, presumably membranous vesicles.
Expression of cathepsin H and ATP binding cassette
transporter A3 (ABCA3) in adult human ATII cells
cultured with IL-13 or IFN-g
SP-B and SP-C are synthesized by ATII cell as proSP-B
and proSP-C, which are proteolytically processed to
mature SP-B and SP-C on route from its site of synth-
esis to the lamellar bodies [53,54]. Cathepsin H is one
of the cysteine proteases involved in the processing of
proSP-B and proSP-C. The first N-terminal processing
step of proSP-C occurs in the electron-dense multivesi-
cular bodies of ATII cells [53,54]. Because IFN-g
decreased protein levels of mature SP-B without a
change in SP-B mRNA, and significantly up-regulated
SP-C mRNA and proSP-C protein without an increase
in mature SP-C (Figure 2C, 3B and 4A), we examined
whether IFN-g changed the level of cathepsin H in ATII
cells. The active form has a molecular size of 28 kDa
[55], and this band was reduced by IFNg but not by
IL-13 (Figure 5A). However, there is no change in pepsi-
nogen C or napsin A, other proteases involved in the
processing of proSP-C (data not shown).
ABCA3 is predominantly expressed in ATII cells and
has been localized to the limiting membrane of lamellar
bodies, which are the main intracellular storage orga-
nelle for pulmonary surfactant [56]. The protein expres-
sion of ABCA3 was measured by immunoblotting, and
it was not altered by either IL-13 or IFN-g (Figure 5B),
which suggests the effect of IL-13 and IFN-g primarily
alter surfactant B and C processing and not lamellar
body formation per se.
Verification of these findings with other culture
conditions in human ATII cells and results with
rat ATII cells
The results above were all done with adult human ATII
cells cultured with 2 d of TGFa and 4 d of KGF. Similar
findings were observed in ATII cells cultured in KGF
( K )a l o n e ,i n2do fKa n d2do fK D( d a t an o ts h o w n )
or in 2 d of KIA and 4 d of KIAD (Additional File 1A
and 1B). The major difference was that in the untreated
conditions, the 2 d of TGFa f o l l o w e db y4do fK G F
showed slightly higher levels of mature SP-C, so that it
was easier to demonstrate a decrease with IL-13. Addi-
tionally, the expression of mature SP-B was not altered
in the KIA + KIAD system by IL-13 or IFN-g
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Page 7 of 13Figure 4 IFN-g increases whereas IL-13 decreases proSP-C. Adult human ATII cells were cultured on Matrigel and rat-tail collagen coated
inserts in DMEM containing 5% heat inactivated human serum for 2 d with10 ng/ml TGFa followed by 4 d 10 ng/ml KGF with or without 4 d
20 ng/ml IL-13 or 100 ng/ml IFN-g. Panel A shows protein levels by immunoblotting for four different proSP-C bands normalized by GAPDH
from 6 different donors cells stimulated by 4 d 20 ng/ml IL-13 or 100 ng/ml IFN-g, which are analyzed by NIH Image. Representative protein
levels by immunoblotting are shown on Figure 1 Panel B lane 3, 5 and 7. White bar: without IL-13 and IFN-g, black bar: with 20 ng/ml IL-13 for 4
d, grey bar: with 100ng/ml IFN-g for 4 d. *: p < 0.05 v.s without IL-13 or IFN-g. Panel B shows immunocytochemistry for proSP-C. Top picture:
without IL-13 or IFN-g, middle one: with IL-13, bottom one: with IFN-g. green: proSP-C, blue: DAPI. These three pictures were taken at the same
exposure times.
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Page 8 of 13Figure 5 IFN-g reduces cathepsin H but not ABCA3. Adult human ATII cells cultured on Matrigel and rat-tail collagen in DMEM containing 5%
heat inactivated human serum with 2 d TGFa followed by 4 d KGF with 20 ng/ml IL-13 or with 100 ng/ml IFN-g for the final 4 days. Panel A
shows representative active form of cathepsin H protein levels by immunoblotting and protein levels by immunoblotting for the active form
cathepsin H normalized by GAPDH from 6 different donors, which are analyzed by NIH Image. Lane 1: day 0 control, Lane 2: empty, Lane 3: 2 d
10 ng/ml TGFa + 4 d 10 ng/ml KGF, Lane 4: 2 d 10 ng/ml TGFa + 4 d 10 ng/ml KGF with 4 d 20 ng/ml IL-13, Lane 5: 2 d 10 ng/ml TGFa +4d
10 ng/ml KGF with 4 d 100 ng/ml IFN-g. White bar: without IL-13 and IFN-g, black bar: with 20 ng/ml IL-13 for 4 d, gray bar: with 100 ng/ml IFN-
g for 4 d. *: p < 0.05 v.s. without IL-13 and IFN-g. Panel B shows representative ABCA3 protein levels by immunoblotting and protein levels by
immunoblotting for ABCA3 normalized by GAPDH from 6 different donors, which are analyzed by NIH Image. Lane order is same as in Panel A.
White bar: without IL-13 and IFN-g, black bar: with 20 ng/ml IL-13 for 4 d, gray bar: with 100 ng/ml IFN-g for 4 d. *: p < 0.05 v.s. without IL-13
and IFN-g.
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tions tested, IL-13 reduced the levels of proSP-C and
mature SP-C and IFN-g increased the level of proSP-C.
Hence, the effects of IL-13 and IFNg on SP-C did not
depend on the differentiation factors that were used for
the human ATII cells.
We cultured rat ATII for 6 d of KGF in DMEM includ-
ing 5% RS with the last 4 d recombinant IL-13 or IFN-g.
The results from rat ATII cells were slightly different
from the observations with human ATII cells. In rat ATII
cells, IL-13 reduced expression of SP-A, mature SP-B,
proSP-C and mature SP-C but not SP-D (Additional File
3A, B, Additional File 2). IFN-g increased SP-A, proSP-C
and SP-D but not mature SP-C (Additional File 3A, B,
Additional File 2). There was clearly incomplete proces-
sing of proSP-C, as indicated by the abundance of the
~22 kDa intermediate. The effects on proSP-C and
mature SP-C by IL-13 and IFN-g were similar in rat and
human ATII cells, whereas the effects on other surfactant
proteins were not (Additional File 2).
Discussion
In this study, we showed that Th1/Th2 cytokines indivi-
dually modulate the expression of surfactant proteins in
adult human ATII cells. IL-13 reduced both mRNA and
protein levels of SP-C and SP-D but did not alter those
of SP-A and SP-B. Interestingly, IFN-g up-regulated the
mRNA level of SP-C and protein level of proSP-C with-
out an increase in mature SP-C. This indicates an altera-
tion in the processing of proSP-C. These changes were
accompanied by down-regulation of the active form of
cathepsin H, which is thought to be required for the
processing of both proSP-B and proSP-C.
We used a different culture system for human type II
cells from the one used in our previous report [48] and
added TGFa to the culture system in this study. Main-
tenance of expression of both pro and mature SP-C is
difficult with adult human ATII cells. Since SP-C levels
were most significantly modified by IL-13 and IFN-g in
this study, we tried several different combinations of
additives including the KIAD system to increase the
expression of mature SP-C. The changes in proSP-C by
IL-13 and IFN-g were similar in all culture systems, but
the expression of mature SP-C was low in the KIAD
system. Therefore, we chose the culture system using 2
d1 0n g / m lT G F - a followed by 4 d 10 ng/ml KGF in
DMEM with 5% heat inactivated human serum, because
this system was the best system for maintaining expres-
sion of mature SP-C (Figure 1A Lane 3 and 2A Lane 3).
The mechanism whereby IL-13 or IFN-g alters the
expression of surfactant protein expression is not com-
pletely defined. However, alterations in surfactant pro-
tein levels can occur as a change in production,
catabolism, processing (in terms of SP-B and SP-C) or a
combination of several abnormalities. In this study, IL-
13 reduced both mRNA and protein levels of SP-C and
SP-D in human adult ATII cells. Our results are differ-
ent from previous reports in rodents, which show that
IL-13-overexpression in mice increases SP-A, SP-B, SP-
Ca n dS P - D[ 3 4 ]a n dt h a t4do f2 0n g / m lI L - 1 3
increases the intracellular SP-D protein level when com-
pared to untreated cells in rat neonatal ATII cells in
vitro [35]. We also performed similar experiments in
vitro with rat adult ATII cells and found that rat IL-13
reduced the protein levels of SP-A, mature SP-B, proSP-
C and mature SP-C, and did not change that of SP-D
(Additional File 3). Although the differences in the
expression of surfactant proteins in response to IL-13
between with human and rat cells in vitro is most likely
due to the species differences, it might also be due to
the age of animals or the experimental systems. The dif-
ferences among overexpressing mice, the human studies
in vitro and rat studies in vitro is complicated because
of the duration of exposure, the dose, compensatory
mechanisms, and systemic effects as well as other con-
founding factors.
IL-13 has been known to play a pivotal role in the
pathogenesis of lung disease such as asthma, IPF, viral
pneumonia and COPD [22,28-33]. SP-D is an important
component of innate immunity in the lungs [1].
Although it is difficult to explain the pathogenesis of
lung diseases due to the dysregulation of only one cyto-
kine, the down-regulation of SP-D in response to IL-13
might modify the pathogenesis of various diseases and
may also alter the susceptibility to pathogens in patients
with these diseases. IPF is proposed to result from
multiple cycles of alveolar epithelial cell injury and acti-
vation instead of chronic inflammatory alveolitis [57].
IL-13 is found at elevated levels in the alveolar macro-
phages of IPF patients [30]. It has also been showed that
human fibroblasts from patients with IPF are hyper-
responsive to IL-13 [58]. Additionally, a high level of IL-
13Ra2 expression is detected in the lung epithelium,
interstitium, and in mononuclear cells in surgical lung
biopsies from patients with IPF [59]. IL-13 is elevated
after administration of bleomycin in murine lungs and
enhanced IL-13Ra2 signaling is thought to be involved
in bleomycin-induced lung fibrosis [60]. Moreover,
some familial forms of pulmonary fibrosis are associated
with mutations in the SP-C gene [7]. Increased and pro-
longed pulmonary fibrosis following intratracheal bleo-
mycin injection is detected in SP-C -/- mice [21]. Our
data reveal that SP-C expression in adult human ATII
cells is reduced in response to IL-13. Taken together, it
is possible that macrophages from patients with IPF
produce IL-13, which decreases the expression of SP-C
in ATII cells and initiates the development of IPF by
producing alveolar instability, because SP-C helps lower
Ito and Mason Respiratory Research 2010, 11:157
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anti-IL-13 therapeutic approaches to IPF (QAX576,
Novartis, phase II clinical trial) have completed, and we
await the results.
SP-B and SP-C are synthesized by ATII cells as pro-
proteins (proSP-B and proSP-C) that are processed to
mature SP-B and SP-C by serial cleavage of NH2-a n d
COOH- terminal peptides [53,54,61-63]. The first pro-
t e a s et ob ea s s o c i a t e dw i t hp r o S P - Bp r o c e s s i n gw a s
cathepsin H [53,61] and inhibition of cathepsin H
results in decreased production of mature SP-B. Napsin
A and pepsinogen C, asparatic proteases, are also
involved in the processing of proSP-B [53,63]. We found
no changes in the protein levels of napsin A or pepsino-
gen C with IL-13 or IFN-g in our studies (data not
shown). On the other hand, the proteolytic processing
of proSP-C to mature SP-C requires at least two distinct
cleavages of the C-terminal propeptide followed by at
least two cleavages of the N-terminal propeptide [64,65].
In the human lung, cathepsin H is involved in the first
N-terminal processing steps of proSP-C in the electron
dense multivesicular bodies in ATII cells [54], but the
proteases for cleavage of other sites are still unknown.
Therefore, considering proSP-B processing steps, we
postulate that the protein levels of mature SP-B are
slightly reduced by IFN-g treatment in the TGFa + KGF
system due to the reduction of the active form cathepe-
sin H. Similarly, the reduction in cathepsin H, along
with the increase in SP-C mRNA, produces a significant
accumulation of proSP-C without an increase in mature
SP-C. Zheng, T., et al. reported that IFN-g causes pro-
tease-antiprotease abnormalities [40], alveolar epithelial
c e l lD N Ai n j u r ya n da p o p t o s i sv i aac a t h e p s i nS -
dependent pathway that leads to emphysema in the
murine lung [37]. In the latter paper, IFN-g overexpres-
sion in mice resulted in an increase in cathepsin H
mRNA levels, which appear inconsistent with our results.
However, their experiment used mice, sustained overex-
pression of IL-13, and analyzed cathepsin H mRNA levels
in the whole lung. Therefore there are many differences
between their experiments and ours. Similarly, in terms
of the expression of surfactant proteins in response to
IFN-g, our results differ from a previous report that
showed in human fetal alveolar epithelial cells, IFN-g
increased the SP-A protein level and mRNA levels, but
did not affect SP-B and SP-C mRNA levels [41]. How-
ever, again there are many differences in experimental
design that could account for the different results.
IFN-g production is stimulated by the innate immune
response during infection, which alters macrophage
function including enhanced pathogen recognition, anti-
gen processing and presentation, stimulation of leuko-
cyte recruitment, and activation of microbicidal effector
functions and an anti-viral state [36]. In this study, we
demonstrated that IFN-g induces SP-D expression in
adult human ATII cells. Likewise, the dual function
NADPH oxides/heme peroxidase (DUOX) 2 which is an
inducible DUOX form in the human primary tracheo-
bronchial epithelial cells and important for monitoring
pathologic changes in the respiratory tract, is highly up-
regulated by IFN-g,p o l y( I : C ) ,o rr h i n o v i r u s[ 6 6 ] .C o n -
sidered together, it is suggested that IFN-g promotes the
host defense mechanism not only in primary immune
cells but also in respiratory epithelial cells.
ABCA3 is necessary for lamellar body biogenesis, SP-B
processing, and lung development late in gestation [67].
ABCA3 deficiency in human and mice leads to
decreased phosphatidylcholine and phosphatidylglycerol
in surfactant, dysgenesis of lamellar bodies, and respira-
tory distress [56,68]. IL-13 and IFN-g alter SP-B, SP-C
and cathepsin H expression diversely in our study. We
thus hypothesized that these cytokines would alter
lamellar body function. However, as shown in Figure 5B,
ABCA3 expression was not changed by these cytokines.
These results focus the effect of IL-13 and IFN-g on
processing of SP-B and SP-C and not lamellar body gen-
esis per se.
The results with rat cells were differed from the
observations with human cells in several ways (Addi-
tional File 2). Therefore, it is important to confirm
observations made with rodent cells with adult human
cells, if the results with rodent cells are to be used to
explain the pathogenesis of adult human lung diseases.
Conclusions
We demonstrate that IL-13 and IFN-g alter the expres-
sion of surfactant proteins in human adult ATII cells
in vitro. Our current study suggests that these cytokines
imbalance, that is Th1/Th2 cytokine imbalance, might
contribute to the pathogenesis of lung diseases by disor-
dering homeostasis in the alveolar space.
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